ExpreS2ion’s platform to be used in a novel Zika vaccine candidate
Hørsholm, Denmark, July 14, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its ExpreS2[ ]platform will be used in the production of the novel Zika-HX vaccine candidate that is being developed by Excivion Ltd., a UK-based biotechnology company. The manufacturing of the Zika-HX vaccine will be conducted together with CPI, a British independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult.In this project, ExpreS[2]ion acts as a service and production platform provider, leveraging its capabilities to produce